SK3602001A3 - Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin - Google Patents
Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin Download PDFInfo
- Publication number
- SK3602001A3 SK3602001A3 SK360-2001A SK3602001A SK3602001A3 SK 3602001 A3 SK3602001 A3 SK 3602001A3 SK 3602001 A SK3602001 A SK 3602001A SK 3602001 A3 SK3602001 A3 SK 3602001A3
- Authority
- SK
- Slovakia
- Prior art keywords
- combination
- gemcitabine
- acetyldinaline
- dose
- tumor
- Prior art date
Links
- VAZAPHZUAVEOMC-UHFFFAOYSA-N tacedinaline Chemical compound C1=CC(NC(=O)C)=CC=C1C(=O)NC1=CC=CC=C1N VAZAPHZUAVEOMC-UHFFFAOYSA-N 0.000 title claims abstract description 116
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 title claims abstract description 73
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 69
- 229960005277 gemcitabine Drugs 0.000 title claims abstract description 63
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 title claims abstract description 34
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 title claims abstract description 30
- 229960004316 cisplatin Drugs 0.000 title claims abstract description 30
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 title claims abstract description 26
- 229960004117 capecitabine Drugs 0.000 title claims abstract description 26
- 201000011510 cancer Diseases 0.000 title claims abstract description 13
- 238000002512 chemotherapy Methods 0.000 title description 5
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims description 23
- 241001465754 Metazoa Species 0.000 claims description 20
- 230000000259 anti-tumor effect Effects 0.000 claims description 14
- 239000002775 capsule Substances 0.000 claims description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 7
- 239000002246 antineoplastic agent Substances 0.000 claims description 7
- 208000037841 lung tumor Diseases 0.000 claims description 7
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 238000001802 infusion Methods 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 230000001394 metastastic effect Effects 0.000 claims description 3
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 3
- 208000023958 prostate neoplasm Diseases 0.000 claims description 3
- 239000008174 sterile solution Substances 0.000 claims description 3
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 claims description 2
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 claims description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 17
- 238000011282 treatment Methods 0.000 description 65
- 230000000694 effects Effects 0.000 description 28
- 230000004044 response Effects 0.000 description 20
- 239000003814 drug Substances 0.000 description 17
- 229940079593 drug Drugs 0.000 description 16
- 231100000331 toxic Toxicity 0.000 description 15
- 230000002588 toxic effect Effects 0.000 description 15
- 231100000682 maximum tolerated dose Toxicity 0.000 description 14
- 238000012360 testing method Methods 0.000 description 13
- 230000000996 additive effect Effects 0.000 description 10
- 229960005144 gemcitabine hydrochloride Drugs 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 239000000654 additive Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 description 6
- 230000003042 antagnostic effect Effects 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 6
- 230000036961 partial effect Effects 0.000 description 6
- 229940053867 xeloda Drugs 0.000 description 6
- 206010067484 Adverse reaction Diseases 0.000 description 5
- 206010047700 Vomiting Diseases 0.000 description 5
- 230000006838 adverse reaction Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000009097 single-agent therapy Methods 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- 206010033128 Ovarian cancer Diseases 0.000 description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 4
- 230000008030 elimination Effects 0.000 description 4
- 238000003379 elimination reaction Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 201000002528 pancreatic cancer Diseases 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 230000005909 tumor killing Effects 0.000 description 4
- 230000008673 vomiting Effects 0.000 description 4
- 230000004584 weight gain Effects 0.000 description 4
- 235000019786 weight gain Nutrition 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 206010053759 Growth retardation Diseases 0.000 description 3
- 206010028813 Nausea Diseases 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 208000037844 advanced solid tumor Diseases 0.000 description 3
- 238000004820 blood count Methods 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 231100000001 growth retardation Toxicity 0.000 description 3
- 208000014829 head and neck neoplasm Diseases 0.000 description 3
- 230000002489 hematologic effect Effects 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 230000008693 nausea Effects 0.000 description 3
- 239000011885 synergistic combination Substances 0.000 description 3
- 206010065553 Bone marrow failure Diseases 0.000 description 2
- 208000005156 Dehydration Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- 208000032140 Sleepiness Diseases 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000003474 anti-emetic effect Effects 0.000 description 2
- 229940125683 antiemetic agent Drugs 0.000 description 2
- 239000002111 antiemetic agent Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 230000000174 oncolytic effect Effects 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 208000037821 progressive disease Diseases 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 206010043554 thrombocytopenia Diseases 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- LQICKZWUNRSEHI-BNHYGAARSA-N 4-amino-1-[(2r,3r,4s,5s)-5-[difluoro(hydroxy)methyl]-3,4-dihydroxyoxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](C(O)(F)F)O1 LQICKZWUNRSEHI-BNHYGAARSA-N 0.000 description 1
- BDYOVGXZAQDDGF-INEUFUBQSA-N 4-amino-1-[(3r,4r)-2,2-difluoro-3,4,5-trihydroxypentanoyl]pyrimidin-2-one Chemical compound NC=1C=CN(C(=O)C(F)(F)[C@H](O)[C@H](O)CO)C(=O)N=1 BDYOVGXZAQDDGF-INEUFUBQSA-N 0.000 description 1
- 208000000187 Abnormal Reflex Diseases 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010066476 Haematological malignancy Diseases 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 208000013038 Hypocalcemia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 208000005485 Thrombocytosis Diseases 0.000 description 1
- 206010045170 Tumour lysis syndrome Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 238000009096 combination chemotherapy Methods 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 229940046044 combinations of antineoplastic agent Drugs 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 231100000226 haematotoxicity Toxicity 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000035859 hyperreflexia Effects 0.000 description 1
- 206010020745 hyperreflexia Diseases 0.000 description 1
- 230000000705 hypocalcaemia Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000011368 intensive chemotherapy Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 150000004712 monophosphates Chemical class 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000011255 standard chemotherapy Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 231100000338 sulforhodamine B assay Toxicity 0.000 description 1
- 238000003210 sulforhodamine B staining Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 208000010380 tumor lysis syndrome Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10180998P | 1998-09-25 | 1998-09-25 | |
| PCT/US1999/015386 WO2000018393A1 (en) | 1998-09-25 | 1999-07-08 | Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK3602001A3 true SK3602001A3 (en) | 2002-07-02 |
Family
ID=22286531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK360-2001A SK3602001A3 (en) | 1998-09-25 | 1999-07-08 | Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin |
Country Status (34)
| Country | Link |
|---|---|
| US (3) | US6469058B1 (ko) |
| EP (1) | EP1115391B1 (ko) |
| JP (1) | JP2002525320A (ko) |
| KR (1) | KR20010075348A (ko) |
| CN (1) | CN1319009A (ko) |
| AP (1) | AP2001002109A0 (ko) |
| AT (1) | ATE225655T1 (ko) |
| AU (1) | AU762079B2 (ko) |
| BG (1) | BG105470A (ko) |
| BR (1) | BR9913952A (ko) |
| CA (1) | CA2342981A1 (ko) |
| CZ (1) | CZ2001905A3 (ko) |
| DE (1) | DE69903458T2 (ko) |
| DK (1) | DK1115391T3 (ko) |
| EA (1) | EA200100369A1 (ko) |
| EE (1) | EE200100187A (ko) |
| ES (1) | ES2185378T3 (ko) |
| GE (1) | GEP20043199B (ko) |
| HK (1) | HK1040190A1 (ko) |
| HR (1) | HRP20010225B1 (ko) |
| HU (1) | HUP0103640A3 (ko) |
| ID (1) | ID30046A (ko) |
| IL (1) | IL141951A0 (ko) |
| IS (1) | IS5888A (ko) |
| NO (1) | NO20011493L (ko) |
| NZ (1) | NZ510504A (ko) |
| OA (1) | OA11659A (ko) |
| PL (1) | PL348673A1 (ko) |
| PT (1) | PT1115391E (ko) |
| SK (1) | SK3602001A3 (ko) |
| TR (1) | TR200100859T2 (ko) |
| WO (1) | WO2000018393A1 (ko) |
| YU (1) | YU22401A (ko) |
| ZA (1) | ZA200102233B (ko) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE225655T1 (de) * | 1998-09-25 | 2002-10-15 | Warner Lambert Co | Chemotherapie des krebses mit acetyldinalin in verbindung mit gemcitabin, capecitabin oder cisplatin |
| CZ20022216A3 (cs) * | 2001-07-02 | 2003-05-14 | Warner-Lambert Company | Kombinační chemoterapie |
| US20080075762A1 (en) * | 2001-10-03 | 2008-03-27 | Paul Tardi | Compositions for delivery of drug combinations |
| US7850990B2 (en) * | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
| CA2383259A1 (en) | 2002-04-23 | 2003-10-23 | Celator Technologies Inc. | Synergistic compositions |
| US20040132825A1 (en) * | 2002-03-04 | 2004-07-08 | Bacopoulos Nicholas G. | Methods of treating cancer with HDAC inhibitors |
| US7456219B2 (en) | 2002-03-04 | 2008-11-25 | Merck Hdac Research, Llc | Polymorphs of suberoylanilide hydroxamic acid |
| NZ567758A (en) * | 2002-03-04 | 2009-07-31 | Merck Hdac Res Llc | Methods of inducing terminal differentiation using suberoylanilide hydrozmic acid (SAHA) |
| AU2003226408B2 (en) * | 2002-04-15 | 2007-06-14 | Sloan-Kettering Institute For Cancer Research | Combination therapy for the treatment of cancer |
| US20070032422A1 (en) | 2002-10-24 | 2007-02-08 | Spectrum Pharmaceuticals, Inc. | Methods, compositions and articles of manufacture for contributing to the treatment of cancers |
| US8026216B2 (en) | 2002-10-24 | 2011-09-27 | Spectrum Pharmaceuticals, Inc. | Methods and compositions for contributing to the treatment of cancers |
| GB0226434D0 (en) * | 2002-11-13 | 2002-12-18 | Astrazeneca Ab | Combination product |
| CA2506085A1 (en) * | 2002-11-15 | 2004-06-03 | Ronald Lynn Merriman | Combination chemotherapy comprising a mek inhibitor and capecitabine for treating cancer |
| EP1643971A2 (en) * | 2003-05-22 | 2006-04-12 | Neopharm, Inc. | Liposomal formulations comprising a combination of two or more active agents |
| PE20050206A1 (es) * | 2003-05-26 | 2005-03-26 | Schering Ag | Composicion farmaceutica que contiene un inhibidor de histona deacetilasa |
| CN100431606C (zh) * | 2004-11-22 | 2008-11-12 | 山东蓝金生物工程有限公司 | 一种抗癌药物组合物 |
| US7957507B2 (en) | 2005-02-28 | 2011-06-07 | Cadman Patrick F | Method and apparatus for modulating a radiation beam |
| CN100443081C (zh) * | 2005-04-05 | 2008-12-17 | 吴一心 | 木犀草素与一种铂类化疗药物联合用于制备抗肿瘤的药物 |
| US8232535B2 (en) | 2005-05-10 | 2012-07-31 | Tomotherapy Incorporated | System and method of treating a patient with radiation therapy |
| WO2007014106A2 (en) | 2005-07-22 | 2007-02-01 | Tomotherapy Incorporated | System and method of delivering radiation therapy to a moving region of interest |
| CA2616272A1 (en) | 2005-07-22 | 2007-02-01 | Tomotherapy Incorporated | System and method of detecting a breathing phase of a patient receiving radiation therapy |
| US7839972B2 (en) | 2005-07-22 | 2010-11-23 | Tomotherapy Incorporated | System and method of evaluating dose delivered by a radiation therapy system |
| US8442287B2 (en) | 2005-07-22 | 2013-05-14 | Tomotherapy Incorporated | Method and system for evaluating quality assurance criteria in delivery of a treatment plan |
| KR20080049716A (ko) * | 2005-07-22 | 2008-06-04 | 토모테라피 인코포레이티드 | 치료 계획의 전달과 관련된 퀄리티 보증 기준을 평가하는방법 및 시스템 |
| CA2616301A1 (en) * | 2005-07-22 | 2007-02-01 | Tomotherapy Incorporated | Method and system for evaluating delivered dose |
| JP5390855B2 (ja) | 2005-07-23 | 2014-01-15 | トモセラピー・インコーポレーテッド | ガントリおよび治療台の協調した動きを利用した放射線療法の撮像およびデリバリー |
| EP2059254B1 (en) * | 2006-08-31 | 2015-04-08 | Spectrum Pharmaceuticals, Inc. | Sensitization of tumor cells to radiation therapy through the administration of endothelin agonists |
| DK2236145T3 (da) * | 2008-01-28 | 2014-08-04 | Nanocarrier Co Ltd | Farmaceutisk sammensætning og kombineret middel |
| FR2937867B1 (fr) * | 2008-11-03 | 2011-03-04 | Biorebus | Association pharmaceutique contenant l acide lipoique et l acide hydroxycitrique a titre de principes actifs. |
| JO3197B1 (ar) | 2009-04-06 | 2018-03-08 | Otsuka Pharma Co Ltd | (مشتقات 2'-دايوكسي-ريبوفيورانوسيل) 1 , 3 , 4, 7- تترا هيدرو- (1, 3) داي آزيبين- 2 - أون لعلاج السرطان |
| WO2012003413A1 (en) * | 2010-06-30 | 2012-01-05 | The Broad Institute, Inc. | Novel solid forms of tacedinaline |
| US8691875B2 (en) | 2011-07-01 | 2014-04-08 | Broad Institute, Inc. | Solid forms of tacedinaline |
| US9308235B2 (en) | 2012-05-09 | 2016-04-12 | Spectrum Pharmaceuticals, Inc. | Treatment of primary and metastatic carcinoma |
| EP2711008A1 (en) | 2012-09-19 | 2014-03-26 | Institut Univ. de Ciència i Tecnologia, S.A. | N6,N6-dimethyladenosine for use in treating or preventing primary and metastatic breast cancer |
| EP2711007A1 (en) | 2012-09-19 | 2014-03-26 | Institut Univ. de Ciència i Tecnologia, S.A. | 4-Aminopyrazolo[3,4-d]pyrimidine for use in treating or preventing primary and metastatic breast and prostate cancer |
| EP2711009A1 (en) | 2012-09-19 | 2014-03-26 | Institut Univ. de Ciència i Tecnologia, S.A. | Compounds for use in treating or preventing primary and metastatic breast and prostate cancer |
| EP2962309B1 (en) | 2013-02-26 | 2022-02-16 | Accuray, Inc. | Electromagnetically actuated multi-leaf collimator |
| US10189797B2 (en) * | 2015-12-30 | 2019-01-29 | Duke University | Chemical modulators of immune checkpoints and therapeutic use |
| US11987579B2 (en) | 2018-07-30 | 2024-05-21 | Duke University | Niclosamide analogues and therapeutic use thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5562925A (en) * | 1970-04-20 | 1996-10-08 | Research Corporation Tech. Inc. | Anti-tumor method |
| NZ219974A (en) * | 1986-04-22 | 1989-08-29 | Goedecke Ag | N-(2'-aminophenyl)-benzamide derivatives, process for their preparation and their use in the control of neoplastic diseases |
| AU671491B2 (en) * | 1992-12-18 | 1996-08-29 | F. Hoffmann-La Roche Ag | N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines |
| AU6878198A (en) | 1997-04-24 | 1998-11-13 | Warner-Lambert Company | Use of acetyldinaline for the manufacture of a medicament for the treatment of renal cell carcinoma |
| US5972986A (en) * | 1997-10-14 | 1999-10-26 | G.D. Searle & Co. | Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia |
| ATE225655T1 (de) * | 1998-09-25 | 2002-10-15 | Warner Lambert Co | Chemotherapie des krebses mit acetyldinalin in verbindung mit gemcitabin, capecitabin oder cisplatin |
-
1999
- 1999-07-08 AT AT99935442T patent/ATE225655T1/de not_active IP Right Cessation
- 1999-07-08 AU AU50921/99A patent/AU762079B2/en not_active Ceased
- 1999-07-08 ID IDW20010901A patent/ID30046A/id unknown
- 1999-07-08 GE GEAP19995872A patent/GEP20043199B/en unknown
- 1999-07-08 PL PL99348673A patent/PL348673A1/xx not_active Application Discontinuation
- 1999-07-08 OA OA1200100078A patent/OA11659A/en unknown
- 1999-07-08 CZ CZ2001905A patent/CZ2001905A3/cs unknown
- 1999-07-08 HU HU0103640A patent/HUP0103640A3/hu unknown
- 1999-07-08 PT PT99935442T patent/PT1115391E/pt unknown
- 1999-07-08 EA EA200100369A patent/EA200100369A1/ru unknown
- 1999-07-08 ES ES99935442T patent/ES2185378T3/es not_active Expired - Lifetime
- 1999-07-08 AP APAP/P/2001/002109A patent/AP2001002109A0/en unknown
- 1999-07-08 US US09/744,130 patent/US6469058B1/en not_active Expired - Fee Related
- 1999-07-08 BR BR9913952-9A patent/BR9913952A/pt not_active IP Right Cessation
- 1999-07-08 YU YU22401A patent/YU22401A/sh unknown
- 1999-07-08 IL IL14195199A patent/IL141951A0/xx unknown
- 1999-07-08 CN CN99811320A patent/CN1319009A/zh active Pending
- 1999-07-08 CA CA002342981A patent/CA2342981A1/en not_active Abandoned
- 1999-07-08 TR TR2001/00859T patent/TR200100859T2/xx unknown
- 1999-07-08 SK SK360-2001A patent/SK3602001A3/sk unknown
- 1999-07-08 WO PCT/US1999/015386 patent/WO2000018393A1/en not_active Application Discontinuation
- 1999-07-08 EE EEP200100187A patent/EE200100187A/xx unknown
- 1999-07-08 EP EP99935442A patent/EP1115391B1/en not_active Expired - Lifetime
- 1999-07-08 DK DK99935442T patent/DK1115391T3/da active
- 1999-07-08 KR KR1020017003794A patent/KR20010075348A/ko not_active Application Discontinuation
- 1999-07-08 DE DE69903458T patent/DE69903458T2/de not_active Expired - Fee Related
- 1999-07-08 JP JP2000571912A patent/JP2002525320A/ja active Pending
- 1999-07-08 NZ NZ510504A patent/NZ510504A/en unknown
-
2001
- 2001-03-14 IS IS5888A patent/IS5888A/is unknown
- 2001-03-16 ZA ZA200102233A patent/ZA200102233B/en unknown
- 2001-03-23 NO NO20011493A patent/NO20011493L/no not_active Application Discontinuation
- 2001-03-23 HR HR20010225A patent/HRP20010225B1/xx not_active Application Discontinuation
- 2001-04-25 BG BG105470A patent/BG105470A/xx unknown
-
2002
- 2002-03-01 HK HK02101589.3A patent/HK1040190A1/zh unknown
- 2002-10-08 US US10/184,309 patent/US20030170300A1/en not_active Abandoned
- 2002-10-09 US US10/185,221 patent/US20030086965A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK3602001A3 (en) | Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin | |
| EP2786753B1 (en) | Combination therapy with an antitumor antibiotic | |
| TW200412937A (en) | Combination chemotherapy | |
| US20120128667A1 (en) | Pentamidine combinations for treating cancer | |
| SK16392002A3 (sk) | Kombinovaná chemoterapia | |
| US20070197607A1 (en) | Continuous Dosing Regimen | |
| US10512648B2 (en) | Tyrosine kinase inhibitors for use in a method of treating cancer in association with a reduced caloric intake | |
| EP1229916A2 (en) | Combination chemotherapy | |
| EP1273296B1 (en) | Combination of acetyldinaline and docetaxel | |
| Dobson et al. | Cancer chemotherapy | |
| US20030134893A1 (en) | Combination chemotherapy | |
| MXPA01003074A (en) | Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin |